- Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru (garetosmab-grts) as the first treatment for adults with fibrodysplasia ossificans progressiva to reduce new heterotopic ossification lesions and flare-ups.
- The approval is based on Phase 3 trial results and introduces a new therapeutic franchise for Regeneron beyond its existing portfolio.
- Pasatru targets a rare and severely disabling condition, expanding Regeneron’s reach in rare disease treatments.
This kind of move into rare disease therapies is part of a broader push across healthcare to develop more precise, technology driven treatments. You can explore other companies linked to this theme through 42 healthcare AI stocks
Regeneron Pharmaceuticals is a US based biotech company that discovers, develops, manufactures, and commercializes medicines for a range of diseases, and this FOP approval sits within its push to build out genetically and molecularly targeted therapies. With a market cap of about $80.9b, the company already operates at large scale in its industry, while still adding new rare disease franchises
2 things going right for Regeneron Pharmaceuticals that this headline doesn’t cover
Advertisement
What Pasatru’s approval means for Regeneron Pharmaceuticals’ pipeline story
The investment story for Regeneron Pharmaceuticals leans on the idea that cash flows from established products can support a broad pipeline in immunology and genetic medicines. Pasatru fits that narrative by turning a targeted biology insight into an approved therapy in a highly specialized setting
“Regeneron’s broad and advancing pipeline, including genetic medicines, positions the company to benefit from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside…”
Read the full Regeneron Pharmaceuticals narrative to see the case behind these numbers
Pasatru’s FDA approval strengthens the part of the thesis that says Regeneron can convert its research platforms like VelocImmune into commercially relevant, precision therapies beyond its EYLEA and Dupixent foundations. It also supports the view that rare diseases can be a meaningful extension of its immunology and genetic medicines focus rather than a sideline
The product also broadens Regeneron’s opportunity set versus peers such as Amgen and Vertex that are pursuing different rare-disease paths. This can help reduce reliance on EYLEA in the long run. The unresolved issue is scale, since FOP is ultra-rare and this launch alone does not answer concerns analysts have raised about the need for larger, diversified revenue streams beyond core ophthalmology
For you as an investor, this approval only really matters in the context of the broader story you believe about how Regeneron turns its pipeline into durable, diversified earnings power over time To ensure you’re always in the loop on how the latest news impacts the investment narrative for Regeneron Pharmaceuticals, head to the community page for Regeneron Pharmaceuticals to never miss an update on the top community narratives
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
MI
mitchell_lawler
The Foxhole
Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap
138
PR
pri_dlp7z6h
Happy for the melanoma patients. It is no surprise that other companies moved up too. It’s the optionality getting priced in
QU
Quantanium5h
There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used
Market might be getting a little ahead of itself here
About NasdaqGS:REGN
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide
See The Free Research Report
Flawless balance sheet and good value
See The Free Research Report
Similar Companies
AbbVie
NasdaqGS:AMGN
Amgen
Market Insights
Picking portfolio winners takes more than hot airAN
Andrew Legget
What Korea’s market says about your index fundMI
Mitchell Lawler
What does frontier-beating open source mean for AI investors?AN
Andrew Legget
Advertisement
Weekly Picks
RI
Rick_Orfordon Starfighters Space·14 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$520.6% undervalued
54followersusers have followed this narrative
·2commentsusers have commented on this narrative
·7likesusers have liked this narrative
JO
John_Ericon MercadoLibre·15 days ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$7.31k73.9% undervalued
99followersusers have followed this narrative
·2commentsusers have commented on this narrative
·15likesusers have liked this narrative
RC
rcb9on PayPal Holdings·15 days ago
Ten Percent More Volume, One Percent More Transaction Margin
Fair Value:US$70.8913.6% undervalued
13followersusers have followed this narrative
·1commentusers have commented on this narrative
·6likesusers have liked this narrative
HE
HedgeYon Micron Technology·7 days ago
Micron – The Memory Bottleneck Behind the AI Supercycle
Fair Value:US$1.25k25.0% undervalued
38followersusers have followed this narrative
·0commentsusers have commented on this narrative
·12likesusers have liked this narrative
RecentlyUpdated Narratives
DA
david_1211213on Robo.ai·about 3 hours ago
Robo.ai (AIIO): A Long-Term Bullish Technical Setup
Fair Value:US$5.6449.8% undervalued
1followerusers have followed this narrative
·7commentsusers have commented on this narrative
·1likeusers have liked this narrative
RO
<img src="https://images.simplywall.st/asset/logos/westredlakegold.com?size=48″ alt=”WRLG logo”>RockeTelleron West Red Lake Gold Mines·about 4 hours ago
This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold
Fair Value:CA$4.3681.4% undervalued
27followersusers have followed this narrative
·8commentsusers have commented on this narrative
·0likesusers have liked this narrative
AS
AstrisCorporateAdvisoryon Okinawa Cellular Telephone·about 5 hours ago
Mobile strategy pays off as churn falls
Fair Value:JPÂ¥3.26k23.3% overvalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28022.3% undervalued
331followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 2 months ago
A wonderful business at reasonable price
Fair Value:US$419.9115.3% overvalued
184followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
KI
KiwiInveston Amazon.com·3 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0944.0% undervalued
209followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
